Previous studies have found that a mutation near the junction of the sixth transmembrane domain (TM6) and the third extracellular loop of the M 5 muscarinic receptor leads to constitutive activation and enhanced agonist affinity for the mutated receptor. These results were consistent with the extended ternary complex model, which predicts a correlation between agonist affinity and constitutive activity. We have introduced the homologous mutation into all five subtypes of the highly conserved muscarinic receptor family; SerThr3 TyrPro was introduced into M 1 and M 5 , and AsnThr3 TyrPro was introduced into M 2 , M 3 , and M 4 . In binding assays, these mutations produced increases in affinities toward acetylcholine and carbachol that ranged from 5-fold at the M 2 receptor to 15-to 20-fold at M 1 , M 3 , and M 4 , to 40-fold at M 5 . In functional assays, all five mutant receptors exhibited constitutive activity, at levels ranging between 30 and 80% of the maximal response elicited by carbachol. In every case, the muscarinic antagonist atropine inhibited this constitutive activity with high affinity. Thus, despite differences in effector coupling and in wild-type sequence at the mutation site, all five subtypes were activated by this mutation at the top of TM6. Previous studies of the M 5 subtype have indicated that TM6 is a ligand-dependent switch that sets the activation state of the receptor. Based on the results of the present study, it is possible that TM6 represents a general switch for the activation of the muscarinic receptor family.
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Muscarinic acetylcholine receptors consist of five subtypes, M 1 -M 5 , all of which have been cloned (Kubo et al., 1986; Bonner et al., 1987 Bonner et al., , 1988 Peralta et al., 1987) . All five subtypes are seven-transmembrane, G-protein-coupled receptors. M 1 , M 3 , and M 5 preferentially couple to G q and stimulate phosphoinositide hydrolysis (Peralta et al., 1987; Bonner et al., 1988; Conklin et al., 1988; Liao et al., 1989) . M 2 and M 4 preferentially couple to G i and inhibit adenylyl cyclase activity (Jones et al., 1988; Peralta et al., 1988) . Although the subtypes differ in respect to which G-proteins they preferentially couple, the amino acid sequences among all five subtypes are highly conserved, especially in the transmembrane regions. For example, the five muscarinic receptors are significantly more closely related to each other than are the ␣ 1 and ␣ 2 adrenergic receptors (Schwartz et al., 1997) . This highly conserved nature of the muscarinic family is believed to be the reason for the difficulty encountered in developing highly selective agents for each of the muscarinic receptor subtypes.
Naturally occurring mutations in G-protein-coupled receptors underlie certain pathologies. In particular, some mutations have been shown to result in constitutive activity or activity in the absence of an agonist. Constitutively activating mutations in the thyrotropin receptor, parathyroid hormone receptor, and luteinizing hormone receptor have been shown to cause hyperfunctioning thyroid adenomas (Parma et al., 1995; Kopp et al., 1997) , Jansen-type metaphyseal chondrodysplasia (Schipani et al., 1995) , and familial male precocious puberty (Laue and Cutler 1994; Kosugi et al., 1995) , respectively. Mutations in recombinant receptors can also elicit constitutive activity. Among these recombinantly expressed receptors are the ␣ 1B -adrenergic receptor (Cotecchia et al., 1990) , ␤ 2 -adrenergic receptor (Samama et al., 1993) , and the dopamine D1 receptor (Cho et al., 1996) . Similarly, the M 1 , M 3 , and M 5 muscarinic acetylcholine receptors have been shown to be constitutively active as a result of a mutation or series of mutations (Bluml et al., 1994; Hogger et al., 1995; Spalding et al., 1995 Spalding et al., , 1997 Spalding et al., , 1998 Lu and Hulme, 1999) . These constitutively active recombinant receptors usually exhibit increased affinity toward agonists, in comparison with the respective wild-type receptors. Exceptions to this rule have included amino acids whose mutation led to constitutive activity, but that were considered to be directly involved in the binding of agonist. Thus, there was not a clear correlation between agonist affinity and constitutive activity in these cases (Spalding et al., 1998) . No examples of constitutively activating mutations have yet been reported for the M 2 and M 4 muscarinic receptor subtypes.
In the M 5 receptor, it was shown that when a SerThr sequence near the junction of TM6 and the third extracellular loop was mutated to TyrPro, the receptor was constitutively activated. In addition, a 40-fold increase in affinity for carbachol was observed as a result of the mutation (Spalding et al., 1995) . When the same mutation was introduced at the homologous position in the M 1 receptor and expressed in A9L cells, it also resulted in similar enhancements of agonist affinity (Huang et al., 1998) .
Because the M 1 and M 5 sequences are identical at these positions and preferentially couple to the same G-protein family, it is perhaps not surprising that the same mutation in these two subtypes leads to similar results. The M 3 subtype differs in its sequence at this position, consisting of AsnThr in place of the SerThr of M 1 and M 5 . The M 2 and M 4 receptors not only share the AsnThr of M 3 in this position, but also differ from the M 1 , M 3 , and M 5 receptors in that they preferentially couple to G i . In view of these specific differences within a background of a high degree of sequence conservation, we were interested to determine whether the M 1 , M 2 , M 3 , and M 4 receptors would be sensitive to the TyrPro mutation that activates the M 5 receptor. We have found that the introduction of this TyrPro mutation results in constitutive activity and a significantly increased affinity toward acetylcholine and carbachol in all five muscarinic receptor subtypes.
Experimental Procedures
Materials. Acetylcholine chloride, atropine sulfate, carbamylcholine chloride, Dulbecco's modified Eagle's medium, o-nitrophenyl-␤-D-galactopyranoside, and Nonidet P-40 were obtained from Sigma (St. Louis, MO). pSI-␤-galactosidase was obtained from Promega (Madison, WI) . Tritiated N-methylscopolamine chloride was purchased from New England Nuclear (Boston, MA).
Mutagenesis and Expression. Mutant receptors were created using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Oligonucleotides of approximately 35 bases in length were designed with the desired base substitutions. The oligonucleotides were annealed to the heat-denatured double-stranded plasmid containing the gene for the receptor and a high fidelity DNA polymerase was used to extend the oligonucleotides. The parental DNA was then digested by a methylation-specific nuclease, resulting in a population of plasmids enriched with the mutated receptor gene. The plasmids were then purified from transformed bacteria using the Maxi Prep kit (QIAGEN, Valencia, CA) and mutations were confirmed by sequencing. COS-7 cells were transfected with either the mutant or wild-type human muscarinic receptor plasmids via the calcium phosphate precipitation method. After 72 h, the cells were harvested, homogenized, and centrifuged at 50,000g for 30 min to obtain membranes. The membranes were frozen as aliquots in 5 mM phosphate buffer, pH 7.4, and stored at Ϫ70°C until use in binding assays.
Membrane Binding Assays. 3 H]NMS and concentrations from 10 pM to 4 mM either acetylcholine or carbachol in 5 mM phosphate buffer at 25°C for 3 h. The assays were terminated by filtration, as described above. Data were expressed as the percent inhibition of specific [
3 H]NMS binding and fitted to the following equation
where R is the right plateau, L is the left plateau, X is the concentration of the inhibitor, C is the IC 50 , and S is related to the slope of the curve. Corrected IC 50 values were calculated according to the equation: Corrected IC 50 ϭ IC 50 /(1 ϩ [ 3 H]NMS/K d ), as previously described (Cheng and Prusoff 1973) .
Functional Assays. Receptor selection and amplification technology (R-SAT) assays were performed as follows: NIH-3T3 cells were plated 1 day before transfection using 7.5 ϫ 10 3 cells in 0.1 ml of media per well of a 96-well plate. Cells were transfected using 0.6 l per well Superfect (QIAGEN) according to the manufacturers instruction using 1.5 to 50 ng per well receptor DNA, 4 ng of G qi5 DNA per well (M 2 and M 4 only) and 40 ng of pSI-␤-galactosidase per well . One day after transfection, media was changed, and cells were combined with ligands in Dulbecco's modified Eagle's medium supplemented with 2% cyto-SF3 synthetic supplement (Kemp Laboratories, Frederick, MD) instead of calf serum to a final volume of 200 l/well. After 5 days in culture, ␤-galactosidase levels were measured as described (Lim and Chae, 1989) . The media was removed and ␤-galactosidase activity was determined by adding 200 l of PBS with 3.5 mM o-nitrophenyl-␤-D-galactopyranoside and 0.5% Nonidet P-40 to each well. The 96-well plates were incubated at room temperature and after 3 h the plates were read at 420 nm on a plate reader (EL 310, Bio-Tek Instruments, Winooski, VT; Molecular Devices, Menlo Park, CA). Absorbance data were fitted to the 4-parameter equation described above for agonist binding.
To estimate receptor expression levels, scaled-up transfections were also carried out in 12-well plates. Corresponding to the 10-fold larger area of the wells, 10 times the amounts of cells, pSI-␤-galactosidase, receptor DNA, and Superfect were employed. The binding of a saturating level of [ 3 H]NMS was determined 48 h after transfection. Cells were rinsed with PBS (containing calcium and magnesium), incubated with 1 nM [ 3 H]NMS in PBS for 60 min at room temperature, and then quickly rinsed twice with ice-cold PBS. Subsequently, the contents of each well were solubilized in 0.5 ml of 1% sodium dodecyl sulfate and added to 5 ml of scintillation fluid. Nonspecific binding was determined as the binding to cells that did not receive any receptor DNA. The total protein content was determined in parallel wells by a modification of the method of Lowry et al. (1951) , using bovine serum albumin as a standard. Under these conditions, we found approximately 20 g of protein per well of a 12-well plate.
Constitutively Activated Muscarinic Receptors
Results Figure 1 shows the location of the mutations in each of the receptors, near the junction of TM6 and the third extracellular loop. The high degree of conservation among the muscarinic subtypes in this region can also be appreciated in this figure. Radioligand binding studies were performed on membranes prepared from COS-7 cells transiently transfected with either wild-type or mutant receptors. The K d values for NMS at the wild-type and mutant receptors ranged from about 0.02 to about 0.05 nM and are shown in Table 1 . The mutation caused less than 1.3-fold effect on NMS affinity at the M 2 subtype and negligible effects at the other subtypes. In Fig. 2 Functional (R-SAT) assays were carried out using NIH-3T3 cells that were transiently transfected with the indicated amounts of receptor DNA (see under Experimental Procedures for assay details). For the M 1 , M 3 , and M 5 receptors, 1.5 to 50 ng of DNA was used per well of a 96-well plate.
As shown in Fig. 4 , the mutant M 1 , M 3 , and M 5 receptors exhibited enhanced basal activity at every transfection level. This enhanced basal activity was inhibited by atropine but could also be further increased by carbachol. Each curve of each figure was fitted to the equation given under Experimental Procedures and from this curve-fitting we were able to estimate basal response, maximally stimulated or inhibited response, and the EC 50 and IC 50 values for carbachol and atropine, respectively. From these values, we calculated the degree of constitutive activity as (basal response Ϫ maximally inhibited response)/(maximally stimulated response Ϫ maximally inhibited response). These values of constitutive activity and the potencies of carbachol and atropine are summarized in Table 3 , along with the receptor expression levels observed in experiments carried out in larger (12-well) plates (see under Experimental Procedures).
Several trends can be noticed in the data in Table 3 for the M 1 , M 3 , and M 5 receptors. As noted above, significant constitutive activity is associated with the mutant receptors at every transfection level, whereas the wild-type receptors do not show significant constitutive activity at any level of transfection. Also, the potency of carbachol is greater at every mutant than at its respective wild-type receptor. Another trend is that the degree of constitutive activity rises with the level of transfection, most strikingly for M 5 -YP and least for M 1 -YP. Along with this increase in constitutive activity, there is an increase in the potency of carbachol at the M 3 and M 5 mutants and a modest decrease in the potency of atropine at all three mutants. The lack of change in carbachol potency at M 1 -YP was paralleled by a relatively modest increase in constitutive activity. In fact, the constitutive activity of M 1 -YP at the highest transfection level may be slightly overestimated due to the lower overall response. Although the constitutive activities of the wild-type receptors did not change, the potency of carbachol increased as the amount of receptor transfected was increased. Similar to the mutant receptors, this trend was most pronounced for M 5 and least for M 1 . These trends were reflected in increased expression levels of both wild-type and mutant receptors with increasing transfection levels.
Response data for the M 2 and M 4 receptors are shown in Fig. 5 and the derived parameters are presented in Table 3 . For those experiments, 50 ng of receptor DNA was cotransfected with the chimeric G-protein G qi5 to allow coupling of these G i -preferring receptors to the R-SAT response. Similar to the results seen with M 1 , M 3 , and M 5 , the mutation led to a significant degree of constitutive activity at M 4 , along with a significant increase in the potency of carbachol. The M 2 mutant displayed even more robust constitutive activity, but the data did not permit a determination of carbachol's potency in this case.
Discussion
The major finding of this study was that homologous mutations produced similar and dramatic effects in each of the five muscarinic receptor subtypes. Substitutions with the sequence tyrosine-proline near the junction of TM6 and the third outer loop led to constitutive activation and to enhanced agonist affinity in binding and response assays. The importance of these residues in these processes was not dependent on the wild-type sequences at the mutation site or on the G-protein-coupling preferences of the subtypes (e.g., compare M 1 and M 4 ). This is the first report of a constitutively activating mutation at the M 2 or M 4 muscarinic receptor subtype. Heptahelical receptors have been found to be sensitive to constitutively activating mutations at many sites within TM and intracellular regions (Pauwels and Wurch, 1998) . Most of these sites lie between the middle of the TM regions and the membrane-adjacent regions of the second and third intracellular loops. In particular, mutations of residues within or adjacent to the "BBXXB" motif found just below TM6, in the C-terminal portion of the third intracellular loop, lead to activation of many receptors. This motif of basic (B) and nonbasic (X) residues has been shown to be a crucial element of G-protein-activating peptides (Okamoto and Nishimoto, 1992) . However, Spalding et al. (1995) used a random saturation approach to construct and screen a library of mutants of the M 5 receptor and isolated a strongly activating mutation at the other end of TM6, adjacent to the third outer loop. This mutant (Ser 465 Thr 466 3 TyrPro), which served as the template for the homologous mutations investigated in the present study, also exhibited a large increase in affinity toward carbachol, in agreement with the predictions of the extended ternary complex model (Samama et al., 1993) .
It was later found that the mutation of Ser 465 alone to a number of different amino acids led to constitutive activity in the M 5 receptor . When the serine was mutated to a large or basic residue, a higher degree of constitutive activity was observed, whereas mutation to a small or acidic residue produced no significant constitutive activity. Agonist affinity correlated with the degree of constitutive activity. Strikingly, the body of functional data from the wild-type receptor and 13 mutants could be reconciled by simply postulating that the mutations altered the isomerization constant (J), which describes the equilibrium between inactive and active forms of the receptor in the absence of ligand. Subsequent studies found that the homologous mutation in the M 1 receptor (ST3 YP) also led to enhanced agonist affinity and, again, that the serine was the key amino acid in the mutation (Huang et al., 1998 (Huang et al., , 1999 . Based on these results, it seems most likely that it is the change of Asn3 Tyr in the M 2 , M 3 , and M 4 receptors that leads to the constitutive activity and to the increase in agonist affinity. Interestingly, Asn and Gln were two of the few substitutions that were not investigated at Ser 465 in the M 5 subtype . From the similarity in the effect of our mutation at M 2 , M 3 , and M 4 , we would also expect that the mutation Ser 243 Asn at this position would have little effect on any of the five subtypes.
For the M 1 , M 3 , and M 5 receptors, four different amounts of receptor DNA were transfected into the NIH-3T3 cells. For the M 3 -YP and M 5 -YP receptors, the levels of constitutive activity varied with levels of DNA transfected, increasing with increasing amounts of DNA. It is well known that receptor activity can be enhanced simply by increasing the overall number of receptors, presumably because the number of receptors in the active conformation will also increase proportionately Kenakin, 1996; Chen et al., 1999 Chen et al., , 2000 . In the present study it seems clear that the constitutive activity is primarily due to the mutation, for a significant amount of constitutive activity was observed in the mutated receptors even when the lowest amounts of DNA were transfected (1.5 ng per well) and the lowest receptor expression was observed. Conversely, significant constitutive activity was not observed in the wild-type receptors even at the highest levels of DNA, where much higher expression levels were found. Nonetheless, there was an effect of transfection level on agonist potency at both wild-type and mutated receptors, except for M 1 -YP. The enhancement of carbachol's affinity with increasing levels of expression would be consistent with the presence of a receptor reserve. This apparent spareness is not inconsistent with the increased constitutive activity observed when receptor levels are increased (discussed above; for a theoretical discussion, see Chen et al. 1999 Chen et al. , 2000 . It is not clear why this effect does not occur at M 1 -YP. A couple of factors could account for the different behavior of M 1 -YP. First, possibly because of protein structure, both wild-type and mutant M 1 receptors may inherently have fewer propensities to adopt an active configuration. Indeed for all parameters measured, both wild-type and mutant forms of M 1 appear to be less easily activated than the corresponding M 3 or M 5 receptors. Second, there could be less receptor spareness for M 1 due to lower expression, but we did not find this to be the case. The levels of expression of M 1 / M 1 -YP were very similar to those of M 3 /M 3 -YP and considerably greater than those of M 5 /M 5 -YP. Finally, given that G-protein-coupled receptors are now known to couple to a much wider array of G-protein-dependent and -independent effectors (Heuss and Gerber, 2000) , and that the R-SAT response integrates a complex combination of signaling events, one cannot assume that M 1 -induced responses are completely equivalent to M 3 or M 5 even though they are highly related receptors. These differences could account for the lower maximal achievable responses for M 1 .
In the extended ternary complex model, antagonists can be defined as neutral or negative, according to their ability to affect the equilibrium between R and R*. A neutral antagonist does not affect the equilibrium between R and R*, but only prevents the binding of agonist to the receptor, thus producing competitive antagonism. A negative antagonist Fig. 3 . Agonist binding studies on wild-type and mutant M 2 and M 4 receptors. Carbachol inhibition binding curves were carried out as described in Fig. 2 . Data represent one of at least three separate experiments. Summary data for acetylcholine and carbachol are shown in Table 2 . Cheng and Prusoff (1973) actually shifts the equilibrium toward R; by virtue of atropine's ability to inhibit the constitutive activity in the present study, it is a negative antagonist. Because the basal states of wild-type receptors are usually strongly shifted toward R, small changes in the isomerization constant J are expected to produce larger changes in agonist affinities than in antagonist affinities . This is exactly the effect that we observed in our binding assays, in which agonist affinities were significantly enhanced by the mutation (Table  2) , whereas antagonist affinity was reduced modestly, if at all (Table 1 ). Carbachol's affinities in the R-SAT assays were also much higher at the mutant receptors than at the wild- Table 3 . f, carbachol, wild-type; Ⅺ, atropine, wild-type; OE, carbachol, M x -YP; ‚, atropine, M x -YP. Data represent two experiments, each performed in duplicate. jpet.aspetjournals.org type receptors (see Table 3 and discussion above); conversely, atropine's affinities at the lowest level of expression of the mutant receptors did not differ very much from those reported in the literature for wild-type receptors (Caulfield and Birdsall, 1998) . We did observe decreases in atropine's potency at the M 3 and M 5 mutants, as expression (and constitutive activity) increased. A decrease in atropine's potency was also seen at M 1 -YP, even though carbachol's potency did not increase (as noted above). Quantitatively, across all three of these receptors, there was a 2-to 3-fold reduction in the affinity with which atropine inhibited the response as constitutive activity rose from about 20 to about 50%. When the activity rose yet higher (M 5 ), atropine's potency continued to fall significantly (Table 3 ). This effect implies that there is a nonlinear coupling between stimulus and response for the inverse agonist and may be the inverse of the effect of receptor reserve on (positive) agonists. We are not aware of any previous reports of this phenomenon with negative antagonists. Claeysen et al. (2000) examined stimulus-response coupling at constitutively active 5-HT 4 receptors transiently expressed in COS-7 cells, but found no evidence for nonlinear coupling with either positive or inverse agonists. Stanton and Beer (1997) demonstrated a receptor reserve in the effects of 5-HT at 5-HT 1A receptors expressed in HeLa cells, but did not evaluate the effects of receptor alkylation on the inverse agonist methiothepin. It was not feasible to employ alkylation experiments in our studies, because of the long duration of the assay. G q -and G i -preferring members of the ␣ adrenergic receptor family are also constitutively activated by a homologous mutation. When Ala 293 of the ␣ 1b receptor was mutated, constitutive activity was observed with every amino acid substitution (Kjelsberg et al., 1992) . In the ␣ 2 adrenergic receptor, mutation of Thr 373 , which is homologous to the Ala 293 in the ␣ 1b receptor, also led to constitutive activity (Ren et al., 1993) . These residues lie within the "BBXXB" motif of the third intracellular loop (described above). However, mutations at these two receptors did not produce the same rank orders of activation. In fact, the converse mutations, ␣ 2 Thr3 Ala and ␣ 1b Ala3 Thr each yielded significant constitutive activity. It remains to be seen whether the muscarinic subtypes are more similar to each other in this regard.
In summary, we have found that a mutation previously reported to result in constitutive activity and enhanced agonist affinity at the M 5 muscarinic receptor exerts similar effects on all of the other members of the family, despite differences in effector coupling and in wild-type sequence at the mutation site. Extensive studies of several regions of the M 5 subtype have suggested that interactions between TM3 and TM6 stabilize conformations of the receptor and that TM6 acts as a ligand-dependent switch (Spalding et al., 1998) . In light of the similar effects of identical mutations at the top of TM6 on constitutive activation and agonist binding in all five subtypes, TM6 may be a general switch for all of the muscarinic receptors.
